# LendingTree, Inc.: financial statements, quarterly

TREE · Nasdaq · CIK 1434621 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tree.md) · [Financials](/companies/tree/financials.md) · [Filings](/companies/tree/filings.md) · [Insiders](/companies/tree/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tree/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [155](/filings/0001434621-24-000026.md) | [134 d](/filings/0001628280-26-016084.md) | [168](/filings/0001434621-25-000011.md) | [210](/filings/0001434621-25-000021.md) | [261](/filings/0001628280-25-047863.md) | [262 d](/filings/0001628280-26-016084.md) | [240](/filings/0001628280-26-029355.md) | [250](/filings/0001628280-26-051187.md) | [308](/filings/0001628280-25-047863.md) | [320 d](/filings/0001628280-26-016084.md) | [327](/filings/0001628280-26-029355.md) | [313](/filings/0001628280-26-051187.md) |
| Cost of revenue | $m | [7.6](/filings/0001434621-24-000026.md) | [8.1 d](/filings/0001628280-26-016084.md) | [8.5](/filings/0001434621-25-000011.md) | [8.4](/filings/0001434621-25-000021.md) | [9.4](/filings/0001628280-25-047863.md) | [9.7 d](/filings/0001628280-26-016084.md) | [9.9](/filings/0001628280-26-029355.md) | [10.0](/filings/0001628280-26-051187.md) | [11.0](/filings/0001628280-25-047863.md) | [11.6 d](/filings/0001628280-26-016084.md) | [11.7](/filings/0001628280-26-029355.md) | [11.3](/filings/0001628280-26-051187.md) |
| Gross profit | $m | [69.1](/filings/0001434621-24-000026.md) | [62.2 d](/filings/0001628280-26-016084.md) | [70.5](/filings/0001434621-25-000011.md) | [72.5](/filings/0001434621-25-000021.md) | [78.6](/filings/0001628280-25-047863.md) | [87.9 d](/filings/0001628280-26-016084.md) | [79.0](/filings/0001628280-26-029355.md) | [85.1](/filings/0001628280-26-051187.md) | [94.6](/filings/0001628280-25-047863.md) | [93.4 d](/filings/0001628280-26-016084.md) | [101](/filings/0001628280-26-029355.md) | [88.8](/filings/0001628280-26-051187.md) |
| Research and development | $m | [10.8](/filings/0001434621-24-000026.md) | [11.1 d](/filings/0001628280-26-016084.md) | [11.9](/filings/0001434621-25-000011.md) | [10.4](/filings/0001434621-25-000021.md) | [11.2](/filings/0001628280-25-047863.md) | [12.9 d](/filings/0001628280-26-016084.md) | [11.9](/filings/0001628280-26-029355.md) | [11.5](/filings/0001628280-26-051187.md) | [11.3](/filings/0001628280-25-047863.md) | [10.6 d](/filings/0001628280-26-016084.md) | [11.5](/filings/0001628280-26-029355.md) | [10.0](/filings/0001628280-26-051187.md) |
| Operating income | $m | [(34.0)](/filings/0001434621-24-000026.md) | [(0.2) d](/filings/0001628280-26-016084.md) | [7.2](/filings/0001434621-25-000011.md) | [9.6](/filings/0001434621-25-000021.md) | [9.9](/filings/0001628280-25-047863.md) | [17.9 d](/filings/0001628280-26-016084.md) | [(7.1)](/filings/0001628280-26-029355.md) | [20.9](/filings/0001628280-26-051187.md) | [28.8](/filings/0001628280-25-047863.md) | [22.2 d](/filings/0001628280-26-016084.md) | [31.1](/filings/0001628280-26-029355.md) | [21.8](/filings/0001628280-26-051187.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.5)](/filings/0001434621-24-000026.md) | [0.4 d](/filings/0001628280-26-016084.md) | [0.6](/filings/0001434621-25-000011.md) | [1.7](/filings/0001434621-25-000021.md) | [0.4](/filings/0001628280-25-047863.md) | [1.6 d](/filings/0001628280-26-016084.md) | [(2.4)](/filings/0001628280-26-029355.md) | [1.9](/filings/0001628280-26-051187.md) | [1.4](/filings/0001628280-25-047863.md) | [(131) d](/filings/0001628280-26-016084.md) | [5.7](/filings/0001628280-26-029355.md) | [4.6](/filings/0001628280-26-051187.md) |
| Net income | $m | [(148)](/filings/0001434621-24-000026.md) | [12.7 d](/filings/0001628280-26-016084.md) | [1.0](/filings/0001628280-25-047863.md) | [7.8](/filings/0001628280-25-047863.md) | [(58.0)](/filings/0001628280-25-047863.md) | [7.5 d](/filings/0001628280-26-016084.md) | [(12.4)](/filings/0001628280-26-051187.md) | [8.9](/filings/0001628280-26-051187.md) | [10.2](/filings/0001628280-25-047863.md) | [145 d](/filings/0001628280-26-016084.md) | [17.3](/filings/0001628280-26-051187.md) | [9.6](/filings/0001628280-26-051187.md) |
| Diluted EPS | $ per share | [(11.43)](/filings/0001434621-24-000026.md) | not reported | [0.08](/filings/0001434621-25-000011.md) | [0.58](/filings/0001434621-25-000021.md) | [(4.34)](/filings/0001628280-25-047863.md) | not reported | [(0.92)](/filings/0001628280-26-029355.md) | [0.65](/filings/0001628280-26-051187.md) | [0.73](/filings/0001628280-25-047863.md) | not reported | [1.22](/filings/0001628280-26-029355.md) | [0.68](/filings/0001628280-26-051187.md) |
| Basic EPS | $ per share | [(11.43)](/filings/0001434621-24-000026.md) | not reported | [0.08](/filings/0001434621-25-000011.md) | [0.58](/filings/0001434621-25-000021.md) | [(4.34)](/filings/0001628280-25-047863.md) | not reported | [(0.92)](/filings/0001628280-26-029355.md) | [0.65](/filings/0001628280-26-051187.md) | [0.75](/filings/0001628280-25-047863.md) | not reported | [1.25](/filings/0001628280-26-029355.md) | [0.69](/filings/0001628280-26-051187.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [176](/filings/0001434621-23-000022.md) | [112](/filings/0001434621-25-000006.md) | [231](/filings/0001434621-24-000013.md) | [66.8](/filings/0001434621-24-000020.md) | [96.8](/filings/0001434621-24-000026.md) | [107](/filings/0001628280-26-016084.md) | [126](/filings/0001434621-25-000011.md) | [149](/filings/0001434621-25-000021.md) | [68.6](/filings/0001628280-25-047863.md) | [81.1](/filings/0001628280-26-051187.md) | [85.5](/filings/0001628280-26-029355.md) | [111](/filings/0001628280-26-051187.md) |
| Current assets | $m | [267](/filings/0001434621-23-000022.md) | [196](/filings/0001434621-25-000006.md) | [326](/filings/0001434621-24-000013.md) | [206](/filings/0001434621-24-000020.md) | [252](/filings/0001434621-24-000026.md) | [238](/filings/0001628280-26-016084.md) | [254](/filings/0001434621-25-000011.md) | [319](/filings/0001434621-25-000021.md) | [259](/filings/0001628280-25-047863.md) | [230](/filings/0001628280-26-051187.md) | [244](/filings/0001628280-26-029355.md) | [300](/filings/0001628280-26-051187.md) |
| Total assets | $m | [885](/filings/0001434621-23-000022.md) | [803](/filings/0001434621-25-000006.md) | [927](/filings/0001434621-24-000013.md) | [802](/filings/0001434621-24-000020.md) | [787](/filings/0001434621-24-000026.md) | [768](/filings/0001628280-26-016084.md) | [777](/filings/0001434621-25-000011.md) | [836](/filings/0001434621-25-000021.md) | [760](/filings/0001628280-25-047863.md) | [856](/filings/0001628280-26-051187.md) | [864](/filings/0001628280-26-029355.md) | [912](/filings/0001628280-26-051187.md) |
| Current liabilities | $m | [71.0](/filings/0001434621-23-000022.md) | [75.6](/filings/0001434621-25-000006.md) | [87.7](/filings/0001434621-24-000013.md) | [113](/filings/0001434621-24-000020.md) | [272](/filings/0001434621-24-000026.md) | [240](/filings/0001628280-26-016084.md) | [213](/filings/0001434621-25-000011.md) | [261](/filings/0001434621-25-000021.md) | [181](/filings/0001628280-25-047863.md) | [137](/filings/0001628280-26-051187.md) | [129](/filings/0001628280-26-029355.md) | [162](/filings/0001628280-26-051187.md) |
| Total liabilities | $m | [782](/filings/0001434621-23-000022.md) | [679](/filings/0001434621-25-000006.md) | [795](/filings/0001434621-24-000013.md) | [656](/filings/0001434621-24-000020.md) | [693](/filings/0001434621-24-000026.md) | [659](/filings/0001628280-26-016084.md) | [673](/filings/0001434621-25-000011.md) | [718](/filings/0001434621-25-000021.md) | [628](/filings/0001628280-25-047863.md) | [569](/filings/0001628280-26-051187.md) | [559](/filings/0001628280-26-029355.md) | [591](/filings/0001628280-26-051187.md) |
| Long-term debt | $m | [626](/filings/0001434621-23-000022.md) | [526](/filings/0001434621-25-000006.md) | [631](/filings/0001434621-24-000013.md) | [468](/filings/0001434621-24-000020.md) | [346](/filings/0001434621-24-000026.md) | [344](/filings/0001628280-26-016084.md) | [388](/filings/0001434621-25-000011.md) | [385](/filings/0001434621-25-000021.md) | [388](/filings/0001628280-25-047863.md) | [388](/filings/0001628280-26-051187.md) | [387](/filings/0001628280-26-029355.md) | [386](/filings/0001628280-26-051187.md) |
| Current portion of debt | $m | [2.5](/filings/0001434621-23-000022.md) | [3.1](/filings/0001434621-25-000006.md) | [14.9](/filings/0001434621-24-000013.md) | [14.9](/filings/0001434621-24-000020.md) | [126](/filings/0001434621-24-000026.md) | [125](/filings/0001628280-26-016084.md) | [106](/filings/0001434621-25-000011.md) | [106](/filings/0001434621-25-000021.md) | [3.9](/filings/0001628280-25-047863.md) | [3.9](/filings/0001628280-26-051187.md) | [3.9](/filings/0001628280-26-029355.md) | [3.9](/filings/0001628280-26-051187.md) |
| Shareholders' equity | $m | [103](/filings/0001434621-24-000026.md) | [124](/filings/0001628280-26-016084.md) | [132](/filings/0001628280-25-047863.md) | [146](/filings/0001628280-25-047863.md) | [94.3](/filings/0001628280-25-047863.md) | [109](/filings/0001628280-26-051187.md) | [104](/filings/0001628280-26-051187.md) | [118](/filings/0001628280-26-051187.md) | [132](/filings/0001628280-25-047863.md) | [287](/filings/0001628280-26-051187.md) | [305](/filings/0001628280-26-051187.md) | [321](/filings/0001628280-26-051187.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [18.5 d](/filings/0001434621-24-000026.md) | [20.9 d](/filings/0001628280-26-016084.md) | [5.7](/filings/0001434621-25-000011.md) | [(4.9) d](/filings/0001434621-25-000021.md) | [45.3 d](/filings/0001628280-25-047863.md) | [16.2 d](/filings/0001628280-26-016084.md) | [(0.2)](/filings/0001628280-26-029355.md) | [28.0 d](/filings/0001628280-26-051187.md) | [28.8 d](/filings/0001628280-25-047863.md) | [16.5 d](/filings/0001628280-26-016084.md) | [11.6](/filings/0001628280-26-029355.md) | [29.2 d](/filings/0001628280-26-051187.md) |
| Capital expenditure | $m | [5.1 d](/filings/0001434621-24-000026.md) | [2.6 d](/filings/0001628280-26-016084.md) | [2.7](/filings/0001434621-25-000011.md) | [2.7 d](/filings/0001434621-25-000021.md) | [2.9 d](/filings/0001628280-25-047863.md) | [2.8 d](/filings/0001628280-26-016084.md) | [3.4](/filings/0001628280-26-029355.md) | [2.7 d](/filings/0001628280-26-051187.md) | [3.3 d](/filings/0001628280-25-047863.md) | [3.0 d](/filings/0001628280-26-016084.md) | [2.8](/filings/0001628280-26-029355.md) | [3.2 d](/filings/0001628280-26-051187.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001434621-23-000022.md) | [0.0 d](/filings/0001434621-25-000006.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.8](/filings/0001434621-23-000022.md) | [12.9](/filings/0001434621-24-000013.md) | [12.9](/filings/0001434621-24-000020.md) | [13.0](/filings/0001434621-24-000026.md) | [13.3](/filings/0001434621-25-000011.md) | [13.4](/filings/0001434621-25-000021.md) | [13.3](/filings/0001628280-25-047863.md) | [13.4](/filings/0001628280-26-029355.md) | [13.7](/filings/0001628280-26-051187.md) | [14.0](/filings/0001628280-25-047863.md) | [14.1](/filings/0001628280-26-029355.md) | [14.1](/filings/0001628280-26-051187.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,039,561 at 2026-07-27, from the cover of the [10-Q filed 2026-07-31](/filings/0001628280-26-051187.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.